Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.

Main|Search|PHGKB



Last Posted: Sep 13, 2018

---

• Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
  Leapman Michael S et al. European urology 2018 Sep
• Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer.
  Chattopadhyay Subhayan et al. Prostate cancer and prostatic diseases 2018 Sep
• Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists.
  Kim Simon P et al. Urologic oncology 2018 Sep
• Early Epigenetic Markers for Precision Medicine.
  Dumitrescu Ramona G et al. Methods in molecular biology (Clifton, N.J.) 2018 18563-17
• Genomic Prostate Score, PI-RADSv2, and Progression in Men with Prostate Cancer on Active Surveillance.
  Kornberg Zachary et al. The Journal of urology 2018 Sep
• Know Your Body. Know Your Family History.
  Sun Hee Rim et al, CDC Blog, August 2018
• Promise and Implementation of Proteomic Prostate Cancer Biomarkers.
  Latosinska Agnieszka et al. Diagnostics (Basel, Switzerland) 2018 Aug 8(3)
• Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.
  Hieronymus Haley et al. eLife 2018 Sep 7
• NICE Advice - Prolaris gene expression assay for assessing long-term risk of prostate cancer progression: © NICE (2016) Prolaris gene expression assay for assessing long-term risk of prostate cancer progression.
  et al. BJU international 2018 Aug 122(2) 173-180
• PRODIGE: PRediction models in prOstate cancer for personalized meDIcine challenGE.
  Alitto A R et al. Future oncology (London, England) 2017 Oct 13(24) 2171-2181

more